132 related articles for article (PubMed ID: 37459571)
21. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
Clappier E; Grardel N; Bakkus M; Rapion J; De Moerloose B; Kastner P; Caye A; Vivent J; Costa V; Ferster A; Lutz P; Mazingue F; Millot F; Plantaz D; Plat G; Plouvier E; Poirée M; Sirvent N; Uyttebroeck A; Yakouben K; Girard S; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
Leukemia; 2015 Nov; 29(11):2154-61. PubMed ID: 26050650
[TBL] [Abstract][Full Text] [Related]
22. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
23. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
24. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.
Bokemeyer A; Eckert C; Meyr F; Koerner G; von Stackelberg A; Ullmann R; Türkmen S; Henze G; Seeger K
Haematologica; 2014 Apr; 99(4):706-14. PubMed ID: 24241490
[TBL] [Abstract][Full Text] [Related]
25. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
26. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Aricò M; Valsecchi MG; Conter V; Rizzari C; Pession A; Messina C; Barisone E; Poggi V; De Rossi G; Locatelli F; Micalizzi MC; Basso G; Masera G
Blood; 2002 Jul; 100(2):420-6. PubMed ID: 12091331
[TBL] [Abstract][Full Text] [Related]
27. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Schrappe M; Reiter A; Ludwig WD; Harbott J; Zimmermann M; Hiddemann W; Niemeyer C; Henze G; Feldges A; Zintl F; Kornhuber B; Ritter J; Welte K; Gadner H; Riehm H
Blood; 2000 Jun; 95(11):3310-22. PubMed ID: 10828010
[TBL] [Abstract][Full Text] [Related]
28. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival.
Forestier E; Heyman M; Andersen MK; Autio K; Blennow E; Borgström G; Golovleva I; Heim S; Heinonen K; Hovland R; Johannsson JH; Kerndrup G; Nordgren A; Rosenquist R; Swolin B; Johansson B; ; ;
Br J Haematol; 2008 Mar; 140(6):665-72. PubMed ID: 18241254
[TBL] [Abstract][Full Text] [Related]
29. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
31. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study.
Testi AM; Attarbaschi A; Valsecchi MG; Möricke A; Cario G; Niggli F; Silvestri D; Bader P; Kuhlen M; Parasole R; Putti MC; Lang P; Flotho C; Mann G; Rizzari C; Barisone E; Locatelli F; Linderkamp C; Lauten M; Suttorp M; Zimmermann M; Basso G; Biondi A; Conter V; Schrappe M;
Eur J Cancer; 2019 Nov; 122():61-71. PubMed ID: 31629941
[TBL] [Abstract][Full Text] [Related]
32. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
Maloney KW; Carroll WL; Carroll AJ; Devidas M; Borowitz MJ; Martin PL; Pullen J; Whitlock JA; Willman CL; Winick NJ; Camitta BM; Hunger SP
Blood; 2010 Aug; 116(7):1045-50. PubMed ID: 20442364
[TBL] [Abstract][Full Text] [Related]
33. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
34. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
35. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
37. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
[TBL] [Abstract][Full Text] [Related]
38. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline-Free Protocol for Favorable-Risk Childhood ALL: A Noninferiority Comparison Between Malaysia-Singapore ALL 2003 and ALL 2010 Studies.
Ariffin H; Chiew EKH; Oh BLZ; Lee SHR; Lim EH; Kham SKY; Abdullah WA; Chan LL; Foo KM; Lam JCM; Chan YH; Lin HP; Quah TC; Tan AM; Yeoh AEJ
J Clin Oncol; 2023 Jul; 41(20):3642-3651. PubMed ID: 37276496
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Effect of
Østergaard A; Enshaei A; Pieters R; Vora A; Horstmann MA; Escherich G; Johansson B; Heyman M; Schmiegelow K; Hoogerbrugge PM; den Boer ML; Kuiper RP; Moorman AV; Boer JM; van Leeuwen FN
Hemasphere; 2023 May; 7(5):e875. PubMed ID: 37153875
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
